Gangliosides of the Vertebrate Nervous System

Journal of Molecular Biology

Volumn 428, Issue 16, 2016, Pages 3325-3336

  Schnaar, Ronald L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

glycan binding protein; glycosphingolipid; lipid raft; receptor tyrosine kinase; sialic acid

Indexed keywords

GANGLIOSIDE; RECEPTOR; POLYSACCHARIDE;

ANIMAL MODEL; BIOCHEMISTRY; CELL MEMBRANE; CONGENITAL DISORDER; DEGENERATIVE DISEASE; GENETIC REGULATION; GLIA CELL; HUMAN; INFORMATION; LIPID BLOOD LEVEL; LIPID RAFT; LIPOGENESIS; MAMMAL; NERVE CELL DIFFERENTIATION; NERVE CELL EXCITABILITY; NERVE FIBER GROWTH; NERVOUS SYSTEM; NERVOUS SYSTEM INJURY; NONHUMAN; PHYSICS; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; REGULATORY MECHANISM; REVIEW; VERTEBRATE; ANIMAL; METABOLISM; NERVE CELL; NEUROLOGIC DISEASE;

ANIMALS; GANGLIOSIDES; HUMANS; NERVOUS SYSTEM; NERVOUS SYSTEM DISEASES; NEURONS; POLYSACCHARIDES; VERTEBRATES;

EID: 84982062283     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2016.05.020     Document Type: Review

References (112)

1. [1] Varki, A., Evolutionary forces shaping the Golgi glycosylation machinery: why cell surface glycans are universal to living cells. Cold Spring Harb. Perspect. Biol., 3, 2011, a005462.
2. [2] Hart, G.W., Copeland, R.J., Glycomics hits the big time. Cell. 143 (2010), 672–676.
3. [3] Taylor, M.E., Drickamer, K., Introduction to Glycobiology. 3rd edit., 2011, Oxford University Press, Oxford, 283.
4. [4] Varki, A., Cummings, R.D., Esko, J.D., Freeze, H.H., Stanley, P., Bertozzi, C.R., et al. Essentials of Glycobiology. 2nd edit., 2009, Cold Spring Harbor Laboratory Press, New York, 784.
5. [5] Gabius, H.J., The Sugar Code. 2009, Wiley-VCH, Weinheim, 569.
6. [6] Schnaar, R.L., Neural functions of glycolipids. Kamerling, J.P., Boons, G.J., Lee, Y.C., Suzuki, A., Taniguchi, N., Voragen, A.G.J., (eds.) Comprehensive Glycoscience. Volume 4: Cell Glycobiology and Development Health and Disease in Glycomedicine, 2007, Elsevier Science, Amsterdam, 323–337.
7. [7] Schnaar, R.L., Gerardy-Schahn, R., Hildebrandt, H., Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease and regeneration. Physiol. Rev. 94 (2014), 461–518.
8. [8] Schengrund, C.L., Gangliosides: glycosphingolipids essential for normal neural development and function. Trends Biochem. Sci., 40, 2015, 406.
9. [9] Yu, R.K., Tsai, Y.T., Ariga, T., Yanagisawa, M., Structures, biosynthesis, and functions of gangliosides—an overview. J. Oleo Sci. 60 (2011), 537–544.
10. [10] Todeschini, A.R., Hakomori, S.I., Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains. Biochim. Biophys. Acta 1780 (2008), 421–433.
11. [11] Jackson, S.N., Colsch, B., Egan, T., Lewis, E.K., Schultz, J.A., Woods, A.S., Gangliosides' analysis by MALDI-ion mobility MS. Analyst 136 (2011), 463–466.
12. [12] Davies, L.R., Varki, A., Why is N-Glycolylneuraminic acid rare in the vertebrate brain?. Top. Curr. Chem. 366 (2015), 31–54.
13. [13] Mlinac, K., Fabris, D., Vukelic, Z., Rozman, M., Heffer, M., Bognar, S.K., Structural analysis of brain ganglioside acetylation patterns in mice with altered ganglioside biosynthesis. Carbohydr. Res. 382C (2013), 1–8.
14. [14] Greis, C., Rosner, H., C-pathway polysialogangliosides in the nervous tissue of vertebrates, reacting with the monoclonal antibody Q211. Brain Res. 517 (1990), 105–110.
15. [15] Ando, S., Hirabayashi, Y., Kon, K., Inagaki, F., Tate, S., Whittaker, V.P., A trisialoganglioside containing a sialyl a2-6 N-acetylgalactosamine residue is a cholinergic-specific antigen, Chol-1a-a. J. Biochem. 111 (1992), 287–290.
16. [16] Okajima, T., Chen, H.H., Ito, H., Kiso, M., Tai, T., Furukawa, K., et al. Molecular cloning and expression of mouse GD1alpha/GT1aalpha/GQ1balpha synthase (ST6GalNAc VI) gene. J. Biol. Chem. 275 (2000), 6717–6723.
17. [17] DeMarco, M.L., Woods, R.J., Atomic-resolution conformational analysis of the GM3 ganglioside in a lipid bilayer and its implications for ganglioside-protein recognition at membrane surfaces. Glycobiology 19 (2009), 344–355.
18. [18] Aureli, M., Mauri, L., Ciampa, M.G., Prinetti, A., Toffano, G., Secchieri, C., et al. GM1 ganglioside: past studies and future potential. Mol. Neurobiol. 53 (2016), 1824–1842.
19. [19] Acquotti, D., Sonnino, S., Use of nuclear magnetic resonance spectroscopy in evaluation of ganglioside structure, conformation, and dynamics. Methods Enzymol. 312 (2000), 247–272.
20. [20] Sonnino, S., Prinetti, A., Membrane domains and the “lipid raft” concept. Curr. Med. Chem. 20 (2013), 4–21.
21. [21] Prinetti, A., Chigorno, V., Prioni, S., Loberto, N., Marano, N., Tettamanti, G., et al. Changes in the lipid turnover, composition, and organization, as sphingolipid-enriched membrane domains, in rat cerebellar granule cells developing in vitro. J. Biol. Chem. 276 (2001), 21,136–21,145.
22. [22] Eggeling, C., Ringemann, C., Medda, R., Schwarzmann, G., Sandhoff, K., Polyakova, S., et al. Direct observation of the nanoscale dynamics of membrane lipids in a living cell. Nature 457 (2009), 1159–1162.
23. [23] Aureli, M., Grassi, S., Prioni, S., Sonnino, S., Prinetti, A., Lipid membrane domains in the brain. Biochim. Biophys. Acta 1851 (2015), 1006–1016.
24. [24] Simons, K., van Meer, G., Lipid sorting in epithelial cells. Biochemistry 27 (1988), 6197–6202.
25. [25] Carquin, M., D'Auria, L., Pollet, H., Bongarzone, E.R., Tyteca, D., Recent progress on lipid lateral heterogeneity in plasma membranes: from rafts to submicrometric domains. Prog. Lipid Res. 62 (2015), 1–24.
26. [26] Cantu, L., Del, F.E., Sonnino, S., Prinetti, A., Gangliosides and the multiscale modulation of membrane structure. Chem. Phys. Lipids 164 (2011), 796–810.
27. [27] Sandhoff, K., Harzer, K., Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis. J. Neurosci. 33 (2013), 10,195–10,208.
28. [28] Walkley, S.U., Neurobiology and cellular pathogenesis of glycolipid storage diseases. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 358 (2003), 893–904.
29. [29] Fishman, P.H., Max, S.R., Tallman, J.F., Brady, R.O., Maclaren, N.K., Cornblath, M., Deficient ganglioside biosynthesis: a novel human sphingolipidosis. Science 187 (1975), 68–70.
30. [30] Max, S.R., Maclaren, N.K., Brady, R.O., Bradley, R.M., Rennels, M.B., Tanaka, J., et al. GM3 (hematoside) sphingolipodystrophy. N. Engl. J. Med. 291 (1974), 929–931.
31. [31] Tanaka, J., Garcia, J.H., Max, S.R., Viloria, J.E., Kamijyo, Y., McLaren, N.K., et al. Cerebral sponginess and GM3 gangliosidosis; ultrastructure and probable pathogenesis. J. Neuropathol. Exp. Neurol. 34 (1975), 249–262.
32. [32] Maclaren, N.K., Max, S.R., Cornblath, M., Brady, R.O., Ozand, P.T., Campbell, J., et al. GM3 gangliosidosis: a novel human sphingolipodystrophy. Pediatrics 57 (1976), 106–110.
33. [33] Simpson, M.A., Cross, H., Gurtz, K., Priestman, D.A., Neville, D.C.A., Reinkensmeier, G., et al. Infantile onset symptomatic epilepsy syndrome caused by homozygous loss of function mutations in GM3 synthase. Nat. Genet. 36 (2004), 1225–1229.
34. [34] Fragaki, K., Ait-El-Mkadem, S., Chaussenot, A., Gire, C., Mengual, R., Bonesso, L., et al. Refractory epilepsy and mitochondrial dysfunction due to GM3 synthase deficiency. Eur. J. Hum. Genet. 21 (2013), 528–534.
35. [35] Boccuto, L., Aoki, K., Flanagan-Steet, H., Chen, C.F., Fan, X., Bartel, F., et al. A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation. Hum. Mol. Genet. 23 (2014), 418–433.
36. [36] Yamashita, T., Hashiramoto, A., Haluzik, M., Mizukami, H., Beck, S., Norton, A., et al. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 3445–3449.
37. [37] Boukhris, A., Schule, R., Loureiro, J.L., Lourenco, C.M., Mundwiller, E., Gonzalez, M.A., et al. Alteration of ganglioside biosynthesis responsible for complex hereditary spastic paraplegia. Am. J. Hum. Genet. 93 (2013), 118–123.
38. [38] Harlalka, G., Lehman, A., Chioza, B., Baple, E., Maroofian, R., Cross, H., et al. Mutations in B4GALNT1 (GM2 synthase) underlie a new disorder of ganglioside biosynthesis. Brain 136 (2013), 3618–3624.
39. [39] Chiavegatto, S., Sun, J., Nelson, R.J., Schnaar, R.L., A functional role for complex gangliosides: motor deficits in GM2/GD2 synthase knockout mice. Exp. Neurol. 166 (2000), 227–234.
40. [40] Pan, B., Fromholt, S.E., Hess, E.J., Crawford, T.O., Griffin, J.W., Sheikh, K.A., et al. Myelin-associated glycoprotein and complementary axonal ligands, gangliosides, mediate axon stability in the CNS and PNS: neuropathology and behavioral deficits in single- and double-null mice. Exp. Neurol. 195 (2005), 208–217.
41. [41] Takamiya, K., Yamamoto, A., Furukawa, K., Yamashiro, S., Shin, M., Okada, M., et al. Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 10,662–10,667.
42. [42] Liu, Y., Wada, R., Kawai, H., Sango, K., Deng, C., Tai, T., et al. A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder. J. Clin. Invest. 103 (1999), 497–505.
43. [43] Sun, J., Shaper, N.L., Itonori, S., Heffer-Lauc, M., Sheikh, K.A., Schnaar, R.L., Myelin-associated glycoprotein (siglec-4) expression is progressively and selectively decreased in the brains of mice lacking complex gangliosides. Glycobiology 14 (2004), 851–857.
44. [44] Sheikh, K.A., Sun, J., Liu, Y., Kawai, H., Crawford, T.O., Proia, R.L., et al. Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 7532–7537.
45. [45] Hakomori, S., The glycosynapse. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 225–232.
46. [46] Lipina, C., Hundal, H.S., Ganglioside GM3 as a gatekeeper of obesity-associated insulin resistance: evidence and mechanisms. FEBS Lett. 589 (2015), 3221–3227.
47. [47] Kabayama, K., Sato, T., Saito, K., Loberto, N., Prinetti, A., Sonnino, S., et al. Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 13,678–13,683.
48. [48] Schnaar, R.L., Brain gangliosides in axon-myelin stability and axon regeneration. FEBS Lett. 584 (2010), 1741–1747.
49. [49] Nave, K.A., Myelination and support of axonal integrity by glia. Nature 468 (2010), 244–252.
50. [50] Trapp, B.D., Andrews, S.B., Cootauco, C., Quarles, R., The myelin-associated glycoprotein is enriched in multivesicular bodies and periaxonal membranes of actively myelinating oligodendrocytes. J. Cell Biol. 109 (1989), 2417–2426.
51. [51] Kelm, S., Pelz, A., Schauer, R., Filbin, M.T., Song, T., de Bellard, M.E., et al. Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily. Curr. Biol. 4 (1994), 965–972.
52. [52] Varki, A., Angata, T., Siglecs—the major subfamily of I-type lectins. Glycobiology 16 (2006), 1R–27R.
53. [53] Macauley, M.S., Crocker, P.R., Paulson, J.C., Siglec-mediated regulation of immune cell function in disease. Nat. Rev. Immunol. 14 (2014), 653–666.
54. [54] Yang, L.J.S., Zeller, C.B., Shaper, N.L., Kiso, M., Hasegawa, A., Shapiro, R.E., et al. Gangliosides are neuronal ligands for myelin-associated glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 814–818.
55. [55] Collins, B.E., Yang, L.J.S., Mukhopadhyay, G., Filbin, M.T., Kiso, M., Hasegawa, A., et al. Sialic acid specificity of myelin-associated glycoprotein binding. J. Biol. Chem. 272 (1997), 1248–1255.
56. [56] Susuki, K., Baba, H., Tohyama, K., Kanai, K., Kuwabara, S., Hirata, K., et al. Gangliosides contribute to stability of paranodal junctions and ion channel clusters in myelinated nerve fibers. Glia 55 (2007), 746–757.
57. [57] Da Silva, J.S., Hasegawa, T., Miyagi, T., Dotti, C.G., Abad-Rodriguez, J., Asymmetric membrane ganglioside sialidase activity specifies axonal fate. Nat. Neurosci. 8 (2005), 606–615.
58. [58] Kappagantula, S., Andrews, M.R., Cheah, M., bad-Rodriguez, J., Dotti, C.G., Fawcett, J.W., Neu3 sialidase-mediated ganglioside conversion is necessary for axon regeneration and is blocked in CNS axons. J. Neurosci. 34 (2014), 2477–2492.
59. [59] Schnaar, R.L., Lopez, P.H., Myelin-associated glycoprotein and its axonal receptors. J. Neurosci. Res. 87 (2009), 3267–3276.
60. [60] Monti, E., Miyagi, T., Structure and function of mammalian sialidases. Top. Curr. Chem. 366 (2015), 183–208.
61. [61] Vyas, A.A., Patel, H.V., Fromholt, S.E., Heffer-Lauc, M., Vyas, K.A., Dang, J., et al. Gangliosides are functional nerve cell ligands for myelin-associated glycoprotein (MAG), an inhibitor of nerve regeneration. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 8412–8417.
62. [62] Vinson, M., Strijbos, P.J., Rowles, A., Facci, L., Moore, S.E., Simmons, D.L., et al. Myelin-associated glycoprotein interacts with ganglioside GT1b: a mechanism for neurite outgrowth inhibition. J. Biol. Chem. 276 (2001), 20,280–20,285.
63. [63] Mehta, N.R., Lopez, P.H., Vyas, A.A., Schnaar, R.L., Gangliosides and Nogo receptors independently mediate myelin-associated glycoprotein inhibition of neurite outgrowth in different nerve cells. J. Biol. Chem. 282 (2007), 27,875–27,886.
64. [64] Yiu, G., He, Z., Glial inhibition of CNS axon regeneration. Nat. Rev. Neurosci. 7 (2006), 617–627.
65. [65] Williams, G., Wood, A., Williams, E.J., Gao, Y., Mercado, M.L., Katz, A., et al. Ganglioside inhibition of neurite outgrowth requires Nogo receptor function: identification of interaction sites and development of novel antagonists. J. Biol. Chem. 283 (2008), 16,641–16,652.
66. [66] Yang, L.J., Lorenzini, I., Vajn, K., Mountney, A., Schramm, L.P., Schnaar, R.L., Sialidase enhances spinal axon outgrowth in vivo. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 11,057–11,062.
67. [67] Mountney, A., Zahner, M.R., Lorenzini, I., Oudega, M., Schramm, L.P., Schnaar, R.L., Sialidase enhances recovery from spinal cord contusion injury. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 11,561–11,566.
68. [68] Mountney, A., Zahner, M.R., Sturgill, E.R., Riley, C.J., Aston, J.W., Oudega, M., et al. Sialidase, chondroitinase ABC, and combination therapy after spinal cord contusion injury. J. Neurotrauma 30 (2013), 181–190.
69. [69] Kaucic, K., Liu, Y., Ladisch, S., Modulation of growth factor signaling by gangliosides: positive or negative?. Methods Enzymol. 417 (2006), 168–185.
70. [70] Liu, Y., Li, R., Ladisch, S., Exogenous ganglioside GD1a enhances epidermal growth factor receptor binding and dimerization. J. Biol. Chem. 279 (2004), 36,481–36,489.
71. [71] Mitsuda, T., Furukawa, K., Fukumoto, S., Miyazaki, H., Urano, T., Furukawa, K., Overexpression of ganglioside GM1 results in the dispersion of platelet-derived growth factor receptor from glycolipid-enriched microdomains and in the suppression of cell growth signals. J. Biol. Chem. 277 (2002), 11,239–11,246.
72. [72] Farooqui, T., Franklin, T., Pearl, D.K., Yates, A.J., Ganglioside GM1 enhances induction by nerve growth factor of a putative dimer of TrkA. J. Neurochem. 68 (1997), 2348–2355.
73. [73] Coskun, U., Grzybek, M., Drechsel, D., Simons, K., Regulation of human EGF receptor by lipids. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 9044–9048.
74. [74] Sekino-Suzuki, N., Yuyama, K., Miki, T., Kaneda, M., Suzuki, H., Yamamoto, N., et al. Involvement of gangliosides in the process of Cbp/PAG phosphorylation by Lyn in developing cerebellar growth cones. J. Neurochem. 124 (2013), 514–522.
75. [75] Prendergast, J., Umanah, G.K., Yoo, S.W., Lagerlof, O., Motari, M.G., Cole, R.N., et al. Ganglioside regulation of AMPA receptor trafficking. J. Neurosci. 34 (2014), 13,246–13,258.
76. [76] Traynelis, S.F., Wollmuth, L.P., McBain, C.J., Menniti, F.S., Vance, K.M., Ogden, K.K., et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol. Rev. 62 (2010), 405–496.
77. [77] Isaac, J.T., Ashby, M.C., McBain, C.J., The role of the GluR2 subunit in AMPA receptor function and synaptic plasticity. Neuron 54 (2007), 859–871.
78. [78] Liu, S.J., Savtchouk, I., Ca(2 +) permeable AMPA receptors switch allegiances: mechanisms and consequences. J. Physiol. 590 (2012), 13–20.
79. [79] Hanley, J.G., Subunit-specific trafficking mechanisms regulating the synaptic expression of Ca-permeable AMPA receptors. Semin. Cell Dev. Biol. 27 (2014), 14–22.
80. [80] Goedert, M., NEURODEGENERATION. Alzheimer's and Parkinson's diseases: the prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science, 349, 2015, 1,255,555.
81. [81] Yanagisawa, K., GM1 ganglioside and Alzheimer's disease. Glycoconj. J. 32 (2015), 87–91.
82. [82] Ariga, T., Pathogenic role of ganglioside metabolism in neurodegenerative diseases. J. Neurosci. Res. 92 (2014), 1227–1242.
83. [83] Yanagisawa, K., Odaka, A., Suzuki, N., Ihara, Y., GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat. Med. 1 (1995), 1062–1066.
84. [84] Matsuzaki, K., Kato, K., Yanagisawa, K., Aß polymerization through interaction with membrane gangliosides. Biochim. Biophys. Acta 1801 (2010), 868–877.
85. [85] Kakio, A., Nishimoto, S., Yanagisawa, K., Kozutsumi, Y., Matsuzaki, K., Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 41 (2002), 7385–7390.
86. [86] Hong, S., Ostaszewski, B.L., Yang, T., O'Malley, T.T., Jin, M., Yanagisawa, K., et al. Soluble Abeta oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuron 82 (2014), 308–319.
87. [87] Ikeda, K., Yamaguchi, T., Fukunaga, S., Hoshino, M., Matsuzaki, K., Mechanism of amyloid beta-protein aggregation mediated by GM1 ganglioside clusters. Biochemistry 50 (2011), 6433–6440.
88. [88] Martinez, Z., Zhu, M., Han, S., Fink, A.L., GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry 46 (2007), 1868–1877.
89. [89] Wu, G., Lu, Z.H., Kulkarni, N., Ledeen, R.W., Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans. J. Neurosci. Res. 90 (2012), 1997–2008.
90. [90] Zamfir, A.D., Neurological analyses: focus on gangliosides and mass spectrometry. Adv. Exp. Med. Biol. 806 (2014), 153–204.
91. [91] Valdes-Gonzalez, T., Goto-Inoue, N., Hirano, W., Ishiyama, H., Hayasaka, T., Setou, M., et al. New approach for glyco- and lipidomics–molecular scanning of human brain gangliosides by TLC-blot and MALDI-QIT-TOF MS. J. Neurochem. 116 (2011), 678–683.
92. [92] Kotani, M., Ozawa, H., Kawashima, I., Ando, S., Tai, T., Generation of one set of monoclonal antibodies specific for a- pathway ganglio-series gangliosides. Biochim. Biophys. Acta 1117 (1992), 97–103.
93. [93] Ozawa, H., Kotani, M., Kawashima, I., Tai, T., Generation of one set of monoclonal antibodies specific for b- pathway ganglio-series gangliosides. Biochim. Biophys. Acta 1123 (1992), 184–190.
94. [94] Schnaar, R.L., Fromholt, S.E., Gong, Y., Vyas, A.A., Laroy, W., Wayman, D.M., et al. Immunoglobulin G-class mouse monoclonal antibodies to major brain gangliosides. Anal. Biochem. 302 (2002), 276–284.
95. [95] Angstrom, J., Teneberg, S., Karlsson, K.A., Delineation and comparison of ganglioside-binding epitopes for the toxins of Vibrio cholerae, Escherichia coli, and Clostridium tetani: evidence for overlapping epitopes. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 11,859–11,863.
96. [96] Heffer-Lauc, M., Viljetic, B., Vajn, K., Schnaar, R.L., Lauc, G., Effects of detergents on the redistribution of gangliosides and GPI-anchored proteins in brain tissue sections. J. Histochem. Cytochem. 55 (2007), 805–812.
97. [97] Heffer-Lauc, M., Lauc, G., Nimrichter, L., Fromholt, S.E., Schnaar, R.L., Membrane redistribution of gangliosides and glycosylphosphatidylinositol-anchored proteins in brain tissue sections under conditions of lipid raft isolation. Biochim. Biophys. Acta 1686 (2005), 200–208.
98. [98] Schnaar, R.L., Isolation of glycosphingolipids. Methods Enzymol. 230 (1994), 348–370.
99. [99] Schnaar, R.L., Needham, L.K., Thin-layer chromatography of glycosphingolipids. Methods Enzymol. 230 (1994), 371–389.
100. [100] Sturgill, E.R., Aoki, K., Lopez, P.H., Colacurcio, D., Vajn, K., Lorenzini, I., et al. Biosynthesis of the major brain gangliosides GD1a and GT1b. Glycobiology 22 (2012), 1289–1301.
101. [101] Skraskova, K., Claude, E., Jones, E.A., Towers, M., Ellis, S.R., Heeren, R.M., Enhanced capabilities for imaging gangliosides in murine brain with matrix-assisted laser desorption/ionization and desorption electrospray ionization mass spectrometry coupled to ion mobility separation. Methods., 2016, 10.1016/j.ymeth.2016.02.014.
102. [102] Weishaupt, N., Caughlin, S., Yeung, K.K., Whitehead, S.N., Differential anatomical expression of ganglioside GM1 species containing d18:1 or d20:1 sphingosine detected by MALDI imaging mass spectrometry in mature rat brain. Front. Neuroanat., 9, 2015, 155.
103. [103] Hirano-Sakamaki, W., Sugiyama, E., Hayasaka, T., Ravid, R., Setou, M., Taki, T., Alzheimer's disease is associated with disordered localization of ganglioside GM1 molecular species in the human dentate gyrus. FEBS Lett. 589 (2015), 3611–3616.
104. [104] Woods, A.S., Colsch, B., Jackson, S.N., Post, J., Baldwin, K., Roux, A., et al. Gangliosides and ceramides change in a mouse model of blast induced traumatic brain injury. ACS Chem. Neurosci. 4 (2013), 594–600.
105. [105] de, H.N., Reiding, K.R., Haberger, M., Reusch, D., Falck, D., Wuhrer, M., Linkage-specific sialic acid derivatization for MALDI-TOF-MS profiling of IgG glycopeptides. Anal. Chem. 87 (2015), 8284–8291.
106. [106] Simons, K., Sampaio, J.L., Membrane organization and lipid rafts. Cold Spring Harb. Perspect. Biol., 3, 2011, a004697.
107. [107] Proia, R.L., Glycosphingolipid functions: insights from engineered mouse models. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 358 (2003), 879–883.
108. [108] Tettamanti, G., Bonali, F., Marchesini, S., Zambotti, V., A new procedure for the extraction, purification and fractionation of brain gangliosides. Biochim. Biophys. Acta 296 (1973), 160–170.
109. [109] Yao, D., McGonigal, R., Barrie, J.A., Cappell, J., Cunningham, M.E., Meehan, G.R., et al. Neuronal expression of GalNAc transferase is sufficient to prevent the age-related neurodegenerative phenotype of complex ganglioside-deficient mice. J. Neurosci. 34 (2014), 880–891.
110. [110] Singh, P., Schimenti, J.C., Bolcun-Filas, E., A mouse geneticist's practical guide to CRISPR applications. Genetics 199 (2015), 1–15.
111. [111] Svennerholm, L., Designation and schematic structure of gangliosides and allied glycosphingolipids. Prog. Brain Res. 101 (1994), XI–XIV.
112. [112] Varki, A., Cummings, R.D., Aebi, M., Packer, N.H., Seeberger, P.H., Esko, J.D., et al. Symbol nomenclature for graphical representations of glycans. Glycobiology 25 (2015), 1323–1324.